Emergent Biosolutions Q4 Earnings Call Highlights [Yahoo! Finance]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
capital via buybacks, resolving a legacy legal matter, and materially deleveraging the balance sheet through a combined $110 million gross debt paydown and a voluntary $100 million term-loan prepayment. Full-year 2025 profitability improved despite lower revenue: total revenue was $743 million , adjusted EBITDA rose to $205 million (up 12%), gross margin expanded by 900 bps , operating cash flow climbed to $171 million , and net leverage fell to 1.9x For 2026 management guided revenue of $720–760 million and adjusted EBITDA of $135–155 million , noting results are impacted by the absence of an “exceptionally strong” $60 million international order in 2025 that contributed roughly $50 million of adjusted EBITDA. Interested in Emergent Biosolutions Inc.? Here are five stocks we like better. 3 Small-Cap Stocks to Watch After the Fed's Rate Cuts Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with management h
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (EBS) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of DirectorsGlobeNewswire
- Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ... [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances [Seeking Alpha]Seeking Alpha
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- EBS's page on the SEC website